One of the biggest challenges facing gene therapy is the development of vectors that direct the activity of therapeutic genes specifically to the sites of disease. To achieve this goal, the restriction of transgene transcription via synthetic promoters that are endowed with multiple specificities represents a particularly promising strategy. Towards this end, we have developed a generally applicable strategy (DCTF system) where a synthetic promoter is driven by an artificial heterodimeric transcription factor whose DNA-binding and transactivating subunits are expressed from two promoters Keywords: cell cycle regulation; DCTF system; leucine zipper; tissue-specific promoter; transcriptional targeting
The dual specificity chimeric transcription factor (DCTF) system has been established for the targeting of proliferating melanoma cells. 1 Two subunits harboring the DNAbinding domain of the yeast transcription factor GAL4 or the transactivation domain of herpes simplex virus VP16 were expressed from the tyrosinase and cyclin A promoter, respectively. Heterodimerization was achieved through the interaction surfaces of the CD4 and the Lck protein kinase. Although proof of principle could be demonstrated by this system, it was clear that the overall transcriptional activity had to be improved for a potential application in cancer gene therapy. 1 Since the CD4-Lck interaction is weak and potential interactions with endogenous molecules might result in the sequestration of the chimeric transcription factor used in the DCTF system, we reasoned that the replacement of the heterodimerization interface would lead to a substantial improvement.
The leucine zippers (LZs) represent particularly strong interaction domains commonly frequent in transcription factors 2 and have been shown to be functional in a heterologous context. [3] [4] [5] Dimerization through LZs is mediated by regularly spaced leucines (heptad repeats) in parallel ␣-helices through hydrophobic interactions, while the choice of the dimerization partner is determined by other amino acids, mainly charged residues forming salt bridges. [6] [7] [8] [9] [10] [11] This is exemplified by the Fos and Jun proteins which preferentially form heterodimers and only have a very limited ability to homodimerize. This specificity is brought about by the positively charged amino with different selectivity. A crucial determinant of the DCTF system is the heterodimerization interface that should provide for a high affinity interaction without interference by endogenous proteins. Here, we describe such a dimerization system based on engineered Fos and Jun leucine zippers. We show the usefulness of this system for the combination of cell type-specific and cell cycle-regulated transcription and demonstrate its functionality in an in vivo setting. Gene Therapy (2001) 8, 725-729. acids in the Jun LZ and the negatively charged residues in the Fos counterpart leading to strong self-repulsion of both proteins. 11, 12 Both, Jun and Fos family members are expressed to variable extents in all cells. To make the Jun/Fos LZs suitable for the DCTF system it was therefore necessary to prevent interactions between the chimeric transcription factors of the DCTF system and the endogenous Jun and Fos proteins. We hypothesized that this could be possible by swapping between the two LZs several of the oppositely charged amino acids involved in heterodimerization.
Based on the resolved crystal structure 12 we introduced three acidic amino acids from c-Fos into the c-Jun LZ (mJun) and three basic amino acids from c-Jun into the cFos LZ (mFos), as depicted in Figure 1a , thereby creating mixed-charged structures. To analyze the oligomerization properties of transcription factors carrying such engineered LZs in the context of the herpes simplex virus VP16 transactivation domain 13 (VP16-mJun) or the yeast GAL4 DNA-binding domain 14 (GAL4-mFos) we investigated the association of in vitro translated proteins by radioimmunoprecipitation (RIP).
35
S-methionine-labeled VP16-Jun proteins (VP16-mJun, VP16-wtJun with a wildtype Jun LZ, and VP16-⌬Jun lacking a dimerization domain; Figure 1b) were mixed with unlabeled GAL4-mFos proteins and immunoprecipitated with an antibody directed against GAL4. Figure 1c shows that the proteins containing engineered LZs formed heterodimers, but that complex formation between VP16-wtJun and GAL4-mFos or VP16-⌬Jun and GAL4-wtFos was prevented. Likewise, VP16-mJun did not interact with GAL4-wtFos in an analogous experiment (not shown).
These observations suggest that the mJun and mFos LZ domains could be suitable for mediating specific intra- cellular protein-protein interactions. We therefore analyzed in the next step the functionality of the VP16-mJun and GAL4-mFos proteins in a cellular environment using the DCTF system. For this purpose, we designed expression constructs where VP16-wtJun, VP16-mJun and VP16-⌬Jun were under the control of the cyclin A promoter, and GAL4-wtFos and GAL4-mFos were driven by a tyrosinase promoter. 1 An SV40 promoter-driven luciferase gene with 10 GAL4 binding sites (10xgal4RE-SVpGL3) served as reporter construct. Cotransfections of melanoma cells (MeWo) in various combinations clearly showed that only the coexpression of the VP16-mJun (pVP-mJun) and GAL4-mFos (pGAL-mFos) proteins gave rise to any significant activity (ෂ1.5-fold SV40 promoter; Figure 2a ). Cotransfection of GAL4-mFos with either VP16-wtJun (pVP-wtJun) or VP16-⌬Jun (pVP⌬Jun) gave only marginal signals (in the range of the promoterless luciferase plasmid pGL3), as did the coexpression of GAL4-wtFos (pGAL-wtFos) with any of the VP16-Jun proteins. Thus, neither the combination of two wild-type LZs, nor the combination of one wild-type and one mutant LZ, was able to enable heterodimerization. The former is presumably due to the sequestration of the recombinant factors by endogenous Fos and Jun proteins, the latter due to structural reasons, as supported by the in vitro association data shown in Figure 1b .
S-methionine, complexed with unlabeled mutated GAL4-mFos and immunoprecipitated with a GAL4-specific antibody. The precipitated proteins were analyzed by SDS-PAGE followed by autoradiography. As a control an empty pGEM4 vector was translated in the presence of 35 S-methionine and complexed with unlabeled GAL4-mFos; as a second control the labeled VP16-⌬Jun was incubated with unlabelled GAL4-mFos. For in vitro transcription/translation assay, the chimeric transcription factors were placed under the control of the T7 promoter. They were excised from the pGAL-wtFos, pGAL-mFos, pVP⌬Jun, pVP-wtJun, and pVPmJun constructs (see legend to Figure 2) as HindIII/XbaI fragments and cloned in the same sites into the pGEM4 vector (Promega, Mannheim, Germany) to yield GAL4-wtFos, GAL4-mFos, VP16-⌬Jun, VP16-wtJun andVP16-mJun. In vitro translation was performed with the TNT T7 quick kit (Promega
We next attempted to optimize the transcriptional activity achievable by the Jun/Fos DCTF system by cloning both expression cassettes into one plasmid in a headto-tail configuration, rationing that this would lead to equimolar concentrations of both subunits in the transfected cell. As shown in Figure 2b , this strategy lead to an ෂ24-fold increase (36:1.5) in luciferase activity in melanoma cells (36-fold SV40 promoter). We also compared the activity of the Jun/Fos DCTF system with that of the previously described CD4-LCK dimerization system. 1 The transcriptional activity of the Jun/Fos 'one-plasmid' system was found to be ෂ7-fold greater relative to the corresponding CD4-LCK system (36:5.5). Overall, the DCTF system described in the present study gives rise to 
g reporter construct (10× gal4RE-SVpGL3). As positive or negative controls, 1 g SV40pGL3 or pGL3 were transfected. (b) Comparative analysis of 'one-plasmid' and 'two-plasmids' DCTF using either mJun/mFos or CD4/LCK dimerization interfaces. In the case of the 'one-plasmid' system, MeWo cells were cotransfected with 1 g of the indicated expression plasmid and 1 g 10× gal4RE-SVpGL3. For the 'two-plasmids' system, cells were cotransfected with 1 g of each expression plasmid and 1 g 10× gal4RE-SVpGL3. The ⌬Jun and ⌬CD4 plasmids lacking a dimerization domain were included as negative controls. The numbers to the right of the bars represent the activity relative to SV40pGL3. Data represent the average of four separate experiments, each performed in duplicate, ± standard deviation. (c) Selective transgene expression in proliferating melanoma cells by the mJun/mFos DCTF system. Cells were cotransfected with 1 g pGALmFos-VP⌬Jun or pGALmFos-VPmJun and 0.5 g of the reporter construct (10× gal4RE-SVpGL3). The cells were then cultured either in normal or in methioninefree medium and assayed for luciferase activity 54 h after-transfection. The graph shows the standardized luciferase activities (ratio of pGALmFosVPmJun to pGALmFos-VP⌬Jun) in G 1 -arrested (methionine-deprived) and growing cells. Data represent the average from four

(pGAL-wtFos). The pGAL-mFos construct was generated as described above and carried the following mutations: E-167→K; E-172→K; E-181→R. The expression of these fusions is driven by the chimeric human tyrosinase promoter containing two tyrosinase enhancers upstream from the basal promoter. 1 The VP16-wtJun was constructed by fusing the c-Jun leucine zipper (amino acids 276-312) 12 to the nuclear localization signal of SV40 large T antigen and the transcriptional activation domain of HSV VP16 (amino acids 411-455) 13 (pVP-wtJun). The pVP-mJun construct was generated as described above and carried the following mutations in the leucine zipper (K-283→E; K-288→E; R-302→E). The expression of this fusion is driven by the human cyclin A promoter (−214 to +100; CycA). 1 To generate the pGALmFos-VP⌬Jun and pGALmFos-VPmJun constructs, the cassettes containing the CycA-driven chimeric transcription factors were cloned in a tail-to-tail orientation into the pGAL-mFos plasmid. The constructs pGALLck-VP⌬CD4 and pGALLck-VPCD4
were obtained by cloning the CycA-driven chimeric transcription factors in a tail-to-tail orientation into the Tyr-LCK plasmid. 1 The human cell lines MeWo 21 
(melanoma), PC3 (prostate carcinoma; ATCC CRL-1435) and NCI-H322 (bronchioloalveolar carcinoma; ATCC CRL-5806) were maintained at 37°C in 5% CO 2 in DMEM or RPMI 1640 supplemented with 10% fetal bovine serum. The MeWo cell line was obtained from Prof I Hart (ICRF, London, UK) and the NCI-H322 cell line from Dr M Favrot (Institut Albert Bonniot, Grenoble, France). Cells were plated on 35 mm (diameter) tissue culture plates at a density yielding 60 to 80% confluency at the time of the transfection with DOTAP as described by the manufacturer (Boehringer Mannheim, Mannheim, Germany). For synchronization in G 1 , cells were cultivated for 48 h in methionine-free medium (GIBCO-BRL, Karlsruhe, Germany) with 1% ITS-A supplement (GIBCO-BRL) after the removal of DNA-DOTAP complexes.
Fifty-four hours after transfection, luciferase activities were determined as described. 22 a Ͼ100-fold higher transcriptional activity compared with the originally published system 1 (36:0.2). It is possible that the performance of the DCTF system can be further improved by incorporating all components into a single plasmid vector, which is particularly relevant if the system is to be used in the context of a viral vector. This should not be difficult in view of the relatively small size of all components (Ͻ3 kb in total excluding the reporter/therapeutic gene).
To assess the cell-type specificity and cell cycle regulation of the 'one-plasmid' Jun/Fos DCTF system we analyzed its transcriptional activity in different cell types (MeWo melanoma, H322 lung cancer and PC3 prostate Gene Therapy carcinoma) and in cycling versus G 1 -arrested cells. The latter cells were obtained by methionine deprivation as described previously. 1 As shown in Figure 2c , the activity in both H322 and PC3 cells was marginal (р3.5% of MeWo). In addition, transcriptional activity was ෂ9-fold greater in normally proliferating relative to G 1 -arrested MeWo cells. Thus, only the cycling target cells provide an environment that allows for the Jun/Fos DCTF system to be active.
Finally, we addressed the functionality of the Jun/Fos DCTF system in vivo. We established melanoma (MeWo) and lung carcinoma (H322) xenografts in nude mice and the pGL3promoter vector or the 'one-plasmid' Jun/Fos DCTF system was injected intratumorally as described in the legend to Figure 3 . To be able to standardize the data and to correct the results for variations in transduction efficiency we co-injected a SV40 promoter Renilla luciferase construct, whose activity can be determined independently from the firefly luciferase expressed by the DCTF system. As shown in Figure 3 , transcriptional activity was readily detectable with the SV40 promoter construct in both tumor types demonstrating that the transfer of naked DNA in these xenografts was successful. Moreover, no significant activities were measured with the control plasmids lacking a functional interaction domain (pGALmFos-VP⌬Jun). Most importantly, the Jun/Fos DCTF system was 48-fold more active in the MeWo xenografts compared with the H322 tumors. These results clearly demonstrate that the Jun/Fos DCTF system is functional in an in vivo setting of experimental melanoma.
In summary, our observations show that LZs can be engineered in a way that they enable a specific and strong interaction of heterologous proteins in an intracellular environment, and that such chimeric proteins also function in vivo. This is exemplified in the present study by the application of this technology to the DCTF system which suffered from a very low transcriptional activity. By incorporating the mJun/mFos dimerization system and expressing the resulting subunits from the same vec- tors it was possible to enhance promoter activity more than 100-fold to a level that makes this system now applicable to gene therapy. In addition to this specific application, the mJun/mFos LZ domains should be useful in addressing many other problems, for example, directing partner proteins to a specific subcellular location, 15 to increase the activity of multi-enzyme systems by virtue of a physical link between the enzymes 16, 17 or to improve the function of heterologous proteins in a gene therapeutic setting by enabling oligomerization. 18 Taken together, our data suggest that the dimerization system described in the present study, and its particular application to the DCTF system, will provide invaluable tools for gene therapy and protein engineering.
